ProShares Ultra NASDAQ Biotechnology
BIB
BIB
21 hedge funds and large institutions have $4.52M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less first-time investments, than exits
New positions opened: | Existing positions closed:
45% less capital invested
Capital invested by funds: $8.2M → $4.52M (-$3.69M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Holders
21
Holding in Top 10
–
Calls
$1.29M
Puts
$1.48M
Top Buyers
| 1 | +$856K | |
| 2 | +$575K | |
| 3 | +$288K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.7K |
| 5 |
S
SignatureFD
Atlanta,
Georgia
|
+$8.63K |
Top Sellers
| 1 | -$2.43M | |
| 2 | -$1.47M | |
| 3 | -$1.08M | |
| 4 |
CCP
Clarity Capital Partners
Newport Beach,
California
|
-$201K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$112K |